Director, Clinical Statistician

$210K - $245K/yr(employer-provided)

Description

Role Summary  You will lead and manage biostatistical activities across a complex portfolio of gene therapy studies and other projects. You will collaborate with cross-functional partners to meet clinical development project deliverables and timelines. This may include, but is not limited to, providing statistical consultation on clinical development plans, clinical trial design and clinical study endpoints, calculating sample size, authoring statistical analysis plans, and providing biostatistical input into clinical development plans, scientific publications and presentations, and regulatory filings.   You will be responsible for the analysis of interim and final data sets and will oversee data and programming deliverables accountable by the CRO.  A remote working model may be considered for exceptional candidates.
About Lexeo
 
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.  
 
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
 
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.

Like this job? Get alerts for similar ones

We'll notify you when matching roles are posted.

CardiovascularClinical DevelopmentNew York, New York
Lexeo Therapeutics

Lexeo Therapeutics

BIOTECHNOLOGY

Gene Therapy

LocationNY - New York
Open Jobs10

Pipeline

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients WiN/A
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 PN/A
Clinical Course Of Disease In Participants With FA-CMN/A
LX1001Phase 1
LX1001Phase 1/2